PURPOSE: To identify prognostic and predictive factors of overall survival (OS), relapse-free survival (RFS) and toxicity for patients with uterine papillary serous carcinoma (UPSC). MATERIALS AND METHODS: Patient, tumor, treatment and relapse characteristics of 135 women with Stages I-IVA UPSC treated between 1980 and 2006 at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) were analyzed using Cox regression models to determine prognostic and predictive factors for OS, RFS and toxicity. RESULTS: Mean follow-up was 5.5 years (range, 0.01-25.2). Median 5-year OS was 52%, and RFS was 42% for all patients. On Cox regression analysis, increasing age, stage, and myometrial invasion were prognostic factors associated with shorter OS and RFS. A paclitaxel-platinum chemotherapy regimen was significantly associated with longer OS (hazard ratio [HR]=0.34, 95% confidence interval [CI] 0.15-0.74, p=0.007) and RFS (HR=0.45, 95% CI 0.22-0.92, p=0.03). RFS was improved for patients treated with RT (HR=0.44, 95% CI 0.25-0.77, p=0.004). The 5-year grade 3+ toxicity rate was 3.5% for those who received RT and was 2.9% for those who did not (p=NS). CONCLUSION: Uterine papillary serous cancer can be an aggressive tumor type with a poor prognosis. RFS was improved by radiation and chemotherapy with few grade 3 or higher complications. Using radiation and paclitaxel-platinum chemotherapy should be attempted whenever feasible for patients with UPSC who do not have distant metastases at diagnosis.
PURPOSE: To identify prognostic and predictive factors of overall survival (OS), relapse-free survival (RFS) and toxicity for patients with uterine papillary serous carcinoma (UPSC). MATERIALS AND METHODS:Patient, tumor, treatment and relapse characteristics of 135 women with Stages I-IVA UPSC treated between 1980 and 2006 at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) were analyzed using Cox regression models to determine prognostic and predictive factors for OS, RFS and toxicity. RESULTS: Mean follow-up was 5.5 years (range, 0.01-25.2). Median 5-year OS was 52%, and RFS was 42% for all patients. On Cox regression analysis, increasing age, stage, and myometrial invasion were prognostic factors associated with shorter OS and RFS. A paclitaxel-platinum chemotherapy regimen was significantly associated with longer OS (hazard ratio [HR]=0.34, 95% confidence interval [CI] 0.15-0.74, p=0.007) and RFS (HR=0.45, 95% CI 0.22-0.92, p=0.03). RFS was improved for patients treated with RT (HR=0.44, 95% CI 0.25-0.77, p=0.004). The 5-year grade 3+ toxicity rate was 3.5% for those who received RT and was 2.9% for those who did not (p=NS). CONCLUSION: Uterine papillary serous cancer can be an aggressive tumor type with a poor prognosis. RFS was improved by radiation and chemotherapy with few grade 3 or higher complications. Using radiation and paclitaxel-platinum chemotherapy should be attempted whenever feasible for patients with UPSC who do not have distant metastases at diagnosis.
Authors: Laura L Holman; Navdeep Pal; David A Iglesias; Pamela T Soliman; Nyla Balakrishnan; Ann Klopp; Russell R Broaddus; Nicole D Fleming; Mark F Munsell; Karen H Lu; Shannon N Westin Journal: Gynecol Oncol Date: 2017-04-30 Impact factor: 5.482
Authors: Anuja Jhingran; Lois M Ramondetta; Diane C Bodurka; Brian M Slomovitz; Jubilee Brown; Lawrence B Levy; Michael E Garcia; Patricia J Eifel; Karen H Lu; Thomas W Burke Journal: Gynecol Oncol Date: 2013-02-04 Impact factor: 5.482
Authors: Marcus E Randall; Virginia Filiaci; D Scott McMeekin; Vivian von Gruenigen; Helen Huang; Catheryn M Yashar; Robert S Mannel; Jae-Weon Kim; Ritu Salani; Paul A DiSilvestro; James J Burke; Thomas Rutherford; Nick M Spirtos; Keith Terada; Penny R Anderson; Wendy R Brewster; William Small; Carol A Aghajanian; David S Miller Journal: J Clin Oncol Date: 2019-04-17 Impact factor: 50.717
Authors: Harriet Belding Eldredge-Hindy; Gary Eastwick; Pramila Rani Anne; Norman G Rosenblum; Russell J Schilder; Raffi Chalian; Allison M Zibelli; Christine H Kim; Robert Den Journal: J Contemp Brachytherapy Date: 2014-09-05